Merger and acquisitions (M&A) in Europe and the Middle East have seen a marked slowdown in 2022 as corporate and financial acquirers turned cautious amid rising economic anxiety. Dealmaking in the region dropped by 11% from January to October 2022, compared with the same period of 2021, according to MergerMarket data. Private equity-led activity took the biggest hit, falling by 23% in value in the period, and contributing heavily to the overall decline. While M&A activity remained resilient in the first months of 2022, it lost momentum as macroeconomic conditions deteriorated throughout the year. In this article, we will explore the reasons behind the recent cooldown in deals, the key trends in the M&A market in 2022 and how they are likely to shape activity in 2023.
In our latest report you will find:
1. M&A activity in 2022
2. Quarterly stats on deal number activity
3. Comparison with 2021
4. 2023 Outlook: A new dealmaking environment?
5. Upcoming trends shaping the M&A market:
- Dry powder, Bolt-on acquisitions, Smaller deals, Carve-outs, Winners and losers, ESG and Distressed M&A
To read the full report, click here.
Download Report
Digital Deception: Fighting Fraud in the Era of Emerging Technology
August 26, 2025
Davin Teo and Henry Chambers, Managing Directors and Co-leaders of Disputes and Investigations Asia wrote an article on digital deception for the Hong Kong Chartered Governance Institute’s CGj August 2025 issue.
Unlocking Federal Real Estate: Efficiency, Partnerships, and the Path Ahead
August 26, 2025
Managing Director Tom Scott and Senior Director Paul Firth, join George Guszcza, President & CEO of the National Institute of Building Sciences, on The GovNavigators Show to discuss trends, challenges, and opportunities shaping the future of federal real estate.
DOJ and HHS collaborate to enhance False Claims Act prosecution
August 25, 2025
In a recent article for Westlaw Today, Managing Directors Jenelle Beavers and Donald Lochabay explore the U.S. government’s new collaboration and enforcement priorities around the False Claims Act (FCA).
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
